JODIE MORRISON

Jodie Morrison stands as a highly respected Venture Partner at Atlas Venture, a leading venture capital firm renowned for its pioneering work in the life sciences sector. In her pivotal role, Jodie is instrumental in the creation and strategic development of innovative biotechnology companies, drawing upon a deep well of operational expertise and leadership acumen.

Her investment focus at Atlas Venture is squarely on early-stage opportunities within the biotechnology and life sciences landscape. Jodie is particularly interested in novel therapeutics, platform technologies, and companies that possess the potential to significantly advance patient care. She is not merely an investor but a dedicated company builder, often taking active roles in guiding these ventures from inception through critical growth phases. This hands-on approach is a hallmark of her contribution, providing invaluable strategic and operational guidance to nascent companies.

Jodie's impressive career background is a testament to her capabilities in the biotech industry. Prior to joining Atlas Venture, she served as the Chief Executive Officer of Keryx Biopharmaceuticals, where she successfully led the company through significant milestones, including the commercialization of Auryxia and its eventual acquisition by Akebia Therapeutics. Before Keryx, she held the CEO position at T2 Biosystems, guiding the company through its initial public offering and the development of its diagnostic platform. Her extensive experience spans drug development, commercialization, fundraising, and mergers and acquisitions, equipping her with a comprehensive understanding of the challenges and opportunities within the life sciences sector.

Throughout her tenure and involvement with Atlas Venture, Jodie Morrison has been deeply involved with numerous successful companies. While her role as a Venture Partner often involves direct company building and board participation rather than traditional direct 'investments' in the public sense, her influence has been critical to the trajectory of several notable ventures. These include her involvement with companies like Akouos, which was acquired by Eli Lilly and Company, and IFM Therapeutics, acquired by Bristol Myers Squibb. She has also contributed significantly to companies such as Third Harmonic Bio and Vedere Bio, often serving on their boards and providing strategic oversight. Her ability to identify promising science and translate it into viable, impactful businesses underscores her value to Atlas Venture and the broader biotech ecosystem.

Jodie Morrison's dedication to fostering innovation and her proven track record of operational excellence make her a key figure in the life sciences venture capital community, driving forward the next generation of biotech breakthroughs.